[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts",
    "summary": "Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=882720025bc4cde3a8b730ff961391dde758c0c55d81a6832b83acd681c0b712",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758235501,
      "headline": "Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts",
      "id": 136818221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=882720025bc4cde3a8b730ff961391dde758c0c55d81a6832b83acd681c0b712"
    }
  },
  {
    "ts": null,
    "headline": "J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why",
    "summary": "J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.",
    "url": "https://finnhub.io/api/news?id=510b253192fdb132cea1ccfd28b93b59fe7115cae0c5a0063e558f4b18cc5161",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758213000,
      "headline": "J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why",
      "id": 136801200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.",
      "url": "https://finnhub.io/api/news?id=510b253192fdb132cea1ccfd28b93b59fe7115cae0c5a0063e558f4b18cc5161"
    }
  },
  {
    "ts": null,
    "headline": "Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case",
    "summary": "Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why I'm bullish on this microcap.",
    "url": "https://finnhub.io/api/news?id=bee0716893cf81327a107421f4275d560f911df23c42a3c77dbe0d7f6be4a128",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758203790,
      "headline": "Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case",
      "id": 136800807,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1762540902/image_1762540902.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why I'm bullish on this microcap.",
      "url": "https://finnhub.io/api/news?id=bee0716893cf81327a107421f4275d560f911df23c42a3c77dbe0d7f6be4a128"
    }
  },
  {
    "ts": null,
    "headline": "J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu",
    "summary": "In a pair of Phase III trials, icotrokinra beat Sotyktu on every skin-clearness measure.",
    "url": "https://finnhub.io/api/news?id=ad16214109f62ba7cdee661cec5185f27b3a9645ddc3f1b084771cfb62fa0d5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758199044,
      "headline": "J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu",
      "id": 136797610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In a pair of Phase III trials, icotrokinra beat Sotyktu on every skin-clearness measure.",
      "url": "https://finnhub.io/api/news?id=ad16214109f62ba7cdee661cec5185f27b3a9645ddc3f1b084771cfb62fa0d5d"
    }
  },
  {
    "ts": null,
    "headline": "J&J launches IVL device in Europe; Medtronic looks at pacing for more patients",
    "summary": "J&J’s Shockwave Javelin intravascular lithotripsy catheter treats people with peripheral artery disease. Elsewhere, Medtronic began a pivotal trial to evaluate its pacemakers in a new patient group.",
    "url": "https://finnhub.io/api/news?id=7f121f4e3525c5647124e0765d8788ba59797adeb37ddf462314a31f0295af7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758197586,
      "headline": "J&J launches IVL device in Europe; Medtronic looks at pacing for more patients",
      "id": 136799544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J’s Shockwave Javelin intravascular lithotripsy catheter treats people with peripheral artery disease. Elsewhere, Medtronic began a pivotal trial to evaluate its pacemakers in a new patient group.",
      "url": "https://finnhub.io/api/news?id=7f121f4e3525c5647124e0765d8788ba59797adeb37ddf462314a31f0295af7e"
    }
  }
]